• Publications
  • Influence
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
The findings indicate that favorable levels of adherence, much of which was assessed via patient self-report, can be achieved in sub-Saharan African settings and that adherence remains a concern in North America.
Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators
Important barriers to adherence are consistent across multiple settings and countries, and Clinicians should use this information to engage in open discussion with patients to promote adherence and identify barriers and facilitators within their own populations.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology
The evidence and safety concerns related to the use of two specific African herbals, which are currently recommended by the Ministry of Health in South Africa and member states for use in HIV: African Potato and Sutherlandia are reviewed.
Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda
Ugandan patients receiving cART can expect an almost normal life expectancy, although there is considerable variability among subgroups of patients.
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection.
Adherence to Antiretroviral Therapy in Sub-Saharan Africa and North America
Montessori et al,52 2000 0.57 (0.54-0.60) Robertson et al,51 2006 0.68 (0.50-0.82) Temoshok and Wald,5
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
A comprehensive review of the literature was used to gather country‐specific data on risk factors, prevalence, number of diagnosed individuals and genotype distribution of the hepatitis C virus (HCV) infection in selected European countries, Canada and Israel.
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Sofosbuvir‐velpatasvir‐voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed.